But look at the hope and goal here. And by the way, just Blue Shield respect, they put this on their formulary. So we're already seeing some traction in action, which is exciting. We hope this disruption will lower, as you saw with naloxone... significant decline in costs. in costs across the spectrum. That's the hope and expectation here as we can anchor then, and we can start to see the cost curve start to move in a different direction and collapse overall. (24:18–24:28)
CLAIM
Asserts that previous actions led to a significant decline in naloxone costs.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.